title: Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia.
abstract: To study the prevalence of osteoporosis and hyperandrogenism in neuroleptic-induced hyperprolactinemia, the authors evaluated 10 patients. Three were amenorrheic, while seven had oligomenorrhea. Nine patients had galactorrhea. The Ferriman-Gallway hirsutism score was 12 +/- 2. Vaginal smear maturation value was 53 +/- 8. Bone density, measured by dual photon absorptionometry in the spine, femoral neck, Ward's triangle, and trochanteric region, was 98 +/- 1.5, 92.7 +/- 3, 88.5 +/- 4.2, and 92.6 +/- 3.3 percentile of controls matched for age, sex, weight, and ethnicity, respectively. Serum prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), dehydroepiandrosterone sulfate (DHEAS), total testosterone, and free testosterone were 82 +/- 10 ng/ml, 8.5 +/- 1.1 mIU/ml, 11.1 +/- 2.6 mIU/ml, 4695 +/- 594 ng/ml, 90 +/- 17 ng%, and 2.36% +/- 0.3%, respectively. Serum thyroid-stimulating hormone (TSH) and free thyroxine index were normal. Bone density strongly correlated with vaginal maturation value (r = 0.904, P less than 0.01). It is concluded that (1) neuroleptic-induced hyperprolactinemia is associated with hirsutism and androgen excess primarily of adrenal origin and (2) a subset of these patients is at an increased risk of developing osteoporosis. It may be possible to identify patients at risk of osteoporosis by examining vaginal smears for maturation value. Early detection and management are imperative in this group of patients.
authors.affiliation: Department of Obstetrics and Gynecology, Wayne State University, Hutzel Hospital, Detroit, Michigan 48201.
authors.forename: K
authors.initials: K
authors.lastname: Ataya
authors.forename: A
authors.initials: A
authors.lastname: Mercado
authors.forename: J
authors.initials: J
authors.lastname: Kartaginer
authors.forename: A
authors.initials: A
authors.lastname: Abbasi
authors.forename: K S
authors.initials: KS
authors.lastname: Moghissi
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001842:Bone and Bones / Q000032:analysis*; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood*; D006065:Gonadotropins, Pituitary / Q000097:blood; D006628:Hirsutism / Q000209:etiology; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D010024:Osteoporosis / Q000209:etiology; D013974:Thyroxine / Q000097:blood
chemical_list: D014150:Antipsychotic Agents; D012739:Gonadal Steroid Hormones; D006065:Gonadotropins, Pituitary; D001971:Bromocriptine; D013974:Thyroxine